Primary Site >> Biliary tract Cancer

Gene >> AES

  • 2008
  • 2009
  • 2012
  • 2015
  • 2017
  • 2018
Ref: Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
PMID: 17851723
Ref: OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma.
PMID: 19727937
Ref: An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
PMID: 22469710
Ref: A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
PMID: 25538178
Ref: Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
PMID: 27783997
Ref: Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases.
PMID: 28668864
Ref: Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
PMID: 28456898
Ref: Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
PMID: 29785570
Ref: The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study.
PMID: 30123344
Ref: Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
PMID: 30255257